Background. Hyperuricemia has a strong association with diabetes mellitus. Hyperuricemia can lead to cardiovascular and renal complications in patients with diabetes. The goal of this study was to compare the effect of sodium-glucose cotransporter-2 (SGLT-2) inhibitors dapagliflozin and empagliflozin on serum uric acid (SUA) levels in patients with type 2 diabetes against traditional oral antihyperglycemic drugs (OADs). Methods. In this double-blind randomized controlled trial, 70 patients with type 2 diabetes and elevated SUA levels were assigned to two treatment groups. Patients in group A received SGLT-2 inhibitors tablet dapagliflozin 5 mg to 10 mg and empagliflozin 10 mg to 25 mg. Group B patients received OADs such as glimepiride, metformin, sitagliptin, gliclazide, and glibenclamide as monotherapy or combination therapy. The changes in SUA level were primary end points while changes in body weight and body mass index (BMI) from baseline to end point were secondary end points. Results. After four weeks of treatment, we noted a significant reduction of mean SUA levels in the SGLT-2 inhibitor group from to  mg/dl versus comparator group from to  mg/dl (). Mean body weight was significantly reduced in the SGLT-2 group from to  kg versus comparator group from to  kg (). Similarly, the mean BMI of patients in the SGLT-2 group was significantly reduced from to  kg/m² versus comparator group from to  kg/m² (). Conclusion. SGLT-2 inhibitors have a strong potential to decrease SUA levels in patients with type 2 diabetes.

中文翻译：

---

钠-葡萄糖协同转运蛋白 2 (SGLT-2) 可降低 2 型糖尿病患者的血清尿酸 (SUA) 水平

背景。高尿酸血症与糖尿病密切相关。高尿酸血症可导致糖尿病患者出现心血管和肾脏并发症。本研究的目的是比较钠-葡萄糖协同转运蛋白 2 (SGLT-2) 抑制剂 dapagliflozin 和 empagliflozin 对 2 型糖尿病患者血清尿酸 (SUA) 水平与传统口服降糖药 (OAD) 的影响。方法. 在这项双盲随机对照试验中，70 名 SUA 水平升高的 2 型糖尿病患者被分配到两个治疗组。A组患者接受SGLT-2抑制剂片剂dapagliflozin 5 mg至10 mg和empagliflozin 10 mg至25 mg。B组患者接受OADs如格列美脲、二甲双胍、西格列汀、格列齐特和格列本脲作为单药或联合治疗。SUA 水平的变化是主要终点，而体重和体重指数（BMI）从基线到终点的变化是次要终点。结果。治疗 4 周后，我们注意到 SGLT-2 抑制剂组的平均 SUA 水平从 到  mg/dl 与比较组 到  毫克/分升 (）。SGLT-2 组的平均体重从 到  kg 与比较组 到  公斤 （）。同样，SGLT-2 组患者的平均 BMI 从 到  kg/m ²与比较组 到  公斤/米² (）。 结论。SGLT-2 抑制剂具有降低 2 型糖尿病患者 SUA 水平的强大潜力。